The following resources related to this article are available online at http://stke.sciencemag.org. Multiple neurotransmitter systems in the striatum converge to regulate the excitability of striatal neurons by activating several heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) that signal to the type 5 adenylyl cyclase (AC5), the key effector enzyme that produces the intracellular second messenger cyclic adenosine monophosphate (cAMP). Plasticity of cAMP signaling in the striatum is thought to play an essential role in the development of drug addiction. We showed that the complex of the ninth regulator of G protein signaling (RGS9-2) with the G protein b subunit (Gb 5 ) critically controlled signaling from dopamine and opioid GPCRs to AC5 in the striatum. RGS9-2/Gb 5 directly interacted with and suppressed the basal activity of AC5. In addition, the RGS9-2/Gb 5 complex attenuated the stimulatory action of Gbg on AC5 by facilitating the GTPase (guanosine triphosphatase) activity of Ga o , thus promoting the formation of the inactive heterotrimer and inhibiting Gbg. Furthermore, by increasing the deactivation rate of Ga i , RGS9-2/Gb 5 facilitated the recovery of AC5 from inhibition. Mice lacking RGS9 showed increased cAMP production and, upon withdrawal from opioid administration, enhanced sensitization of AC5. Our findings establish RGS9-2/Gb 5 complexes as regulators of three key aspects of cAMP signaling: basal activity, sensitization, and temporal kinetics of AC5, thus highlighting the role of this complex in regulating both inhibitory and stimulatory GPCRs that shape cAMP signaling in the striatum.
INTRODUCTION
Signaling through heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) regulates many processes in the nervous system, including neurotransmitter release and excitability, and is implicated in the pathogenesis of many neuropsychiatric disorders including schizophrenia, hyperactivity, and drug addiction (1) . Activation of a GPCR by neurotransmitters promotes guanosine 5′-triphosphate (GTP) binding to the a subunits of the downstream G proteins (Ga), resulting in their dissociation into a-GTP and bg subunits. When dissociated, G protein subunits modulate the activity of downstream effector proteins (2, 3) . A key G protein effector is adenylyl cyclase (AC), an enzyme that catalyzes the synthesis of the second messenger cyclic adenosine monophosphate (cAMP). Many AC isoforms are stimulated by Ga s , inhibited by Ga i , and differentially regulated by bg subunits (4) . Modulation of the AC activity is essential for shaping many processes including learning and memory, drug dependence, and motor control (5) .
The regulators of G protein signaling (RGSs) proteins are critical elements of the G protein pathways that limit the extent of the GPCR signaling by acting as guanosine triphosphatase (GTPase) activating proteins (GAPs) for the Ga subunits, thereby promoting their inactivation (6) . The R7 family of RGS proteins (R7 RGS), comprising RGS6, RGS7, RGS9, and RGS11, play particularly important roles in the nervous system, where they control vision, nociception, and reward behavior (7) . All R7 RGS proteins exist as obligate complexes with the type 5 G protein b subunit (Gb 5 ), which is essential for the structural integrity and proteolytic stability of the R7 RGS complex (7) .
The striatum is a structure in the brain that heavily relies on GPCR signaling and is a gateway nucleus of the mesolimbic system that plays an essential role in motor coordination, procedural learning, and drug addiction (8, 9) . In striatal neurons, multiple GPCR pathways, including signaling through dopamine and opioid receptors, converge at the regulation of the type 5 adenylyl cyclase (AC5), a major G protein effector that accounts for about 80% of AC activity in the striatum (10) and mediates many of the striatum-dependent behavioral responses (10) (11) (12) (13) . However, our understanding of how the G protein signaling to AC5 in the striatum is regulated is fragmented at best.
Here, we report that the striatal R7 RGS complex RGS9-2/Gb 5 is the key regulator of the three most fundamental aspects of AC5 action: basal activity, sensitivity, and timing of cAMP signaling. We found that RGS9-2, through its unique C terminus, forms a complex with AC5 in the striatum, inhibits AC5 activity, and accelerates the recovery of AC5 activity from inhibitory G protein regulation. Furthermore, we show that RGS9-2/Gb 5 inhibits AC5 sensitization by a mechanism that involves direct allosteric effects and GAP activity and that reduces stimulatory action of the G protein bg subunits. As a result, mice lacking RGS9-2 produce more cAMP in the striatum during withdrawal from opioids. content in Gb 5 −/− tissues resulted from significantly higher basal activity (Fig. 1B) . The higher cAMP production was accompanied by more efficient cAMP-dependent activation of cAMP-dependent protein kinase (PKA) (Fig. 1C ) and increased phosphorylation of its targets including key striatal regulator DARPP-32 (dopamine-and cAMP-regulated phosphoprotein, 32 kD; Fig. 1D ). We did not observe changes in the abundance of striatal AC5, indicating that the increase in AC activity cannot be explained by changes in its abundance. We next reconstituted striatal membranes with the individual recombinant RGS/Gb 5 complexes and found that they inhibited basal AC activity. Of the three proteins tested, the RGS9-2/Gb 5 complex, which is enriched in the striatum, displayed the highest inhibitory effect; RGS6/Gb 5 had a weaker inhibitory effect; and RGS7/Gb 5 showed no significant regulation (Fig. 1E ). These observations suggest that RGS/Gb 5 complexes suppress AC activity in the striatum.
RGS9-2/Gb 5 desensitizes AC5 to the stimulatory action of Ga s
Increased AC activity upon elimination of RGS/Gb 5 complexes is paradoxical because these RGS proteins inhibit the Ga i/o class of G proteins (15, 16) , which inhibit AC. Therefore, it would be expected that Gb 5 deficiency would cause decreased cAMP production due to an increase in Ga i -mediated inhibitory influence. However, the striatally enriched AC5 isoform is also allosterically modulated by the direct interaction with RGS proteins (for example, RGS2), which inhibit AC5 stimulation by Ga s and bg subunits (17) . Members of the G i/o family readily release bg subunits upon activation, making them available for regulation of ACs. The GAP activity of RGS proteins promotes heterotrimer reassembly; hence, elimination of RGS/Gb 5 proteins may also sensitize ACs by increasing the availability of free bg subunits in addition to removing the potential direct inhibitory influence. Indeed, activation of the Ga s -coupled D 1 receptor produced greater AC stimulation in membranes from the striatum of Gb 5 knockout mice compared to those from wild-type animals ( Fig. 2A) . To provide a more mechanistic insight into observed sensitization, we analyzed the doseresponse relationship of AC stimulation by activated Ga s in striatal membrane preparations (Fig. 2B ). The addition of the Gbg subunits caused a robust leftward shift, indicating a sensitizing action (Fig. 2B) . In contrast, the addition of the RGS9-2/Gb 5 complex shifted the curve to the right, indicating a desensitizing effect (Fig. 2B ). To discriminate between direct inhibitory effects and bg-mediated effects, we next tested the impact of the GAP-deficient N364H mutant of RGS9-2 (18), which eliminated the effect of RGS9-2 on Gbg signaling ( fig. S1 ). The N364H mutant was as effective in desensitizing AC activity as the wild type, indicating that RGS9-2 can inhibit AC activity by a mechanism independent of its effect on the G protein cycle (Fig. 2B) . Similarly, the inhibitory effect of both wild-type recombinant RGS9-2/Gb 5 complex and its N364H mutant (at 0.5 mM) was observed upon stimulation of AC through the activation of the D 1 receptors by dihydrexidine (DHX) (Fig. 2C) .
Because AC5 is the predominant AC isoform in the striatum, we next studied the effects of the RGS9-2/Gb 5 complex on ectopically expressed AC5 in transfected human embryonic kidney (HEK) 293T cells. The RGS complex significantly diminished both forskolin-and isoproterenolstimulated AC5 activity in the transfected cells without affecting the abundance of AC5 (Fig. 2D ). RGS9-2/Gb 5 had no effect on the cAMP production catalyzed by the endogenous AC in these cells (Fig. 2D) . Furthermore, purified recombinant RGS9-2/Gb 5 complex inhibited the basal activity of recombinant AC5 expressed in insect Sf 9 cells in a dose-dependent manner, an effect that was also seen with the GAP-deficient N364H mutant (Fig. 2E) . Overall, these observations suggest that RGS/Gb 5 complexes inhibit the activity of the AC5 isoform.
RGS9-2/Gb 5 forms a physical complex with AC5
To understand why RGS9-2 was the most effective isoform of Gb 5 -binding RGS proteins in regulating AC5 activity and could act in a GAP-independent fashion, we tested the possibility that RGS9-2 may form a physical complex with AC5 in the striatum. Indeed, when RGS9-2 was immunoprecipitated from the wild-type striatum, it co-eluted with a considerable amount of AC activity (Fig. 3A) , whereas control experiments performed with RGS9 knockout striatal tissues showed virtually no AC activity in the eluates. Conversely, Flag-tagged AC5 retained on the beads captured from transfected cells effectively pulled down RGS9-2 from total striatal lysates (Fig.  3B ). In addition, AC5 and RGS9-2 cotransfected in HEK293T cells robustly co-immunoprecipitated each other (Fig. 3C) . We next delineated the binding determinants of the interaction using recombinant proteins (Fig. 3D) . The RGS9-2/Gb 5 complex bound to the reconstituted cytoplasmic C1/C2 domains but not to the N terminus of AC5 (Fig.  3E) . Deletional mutagenesis of RGS9-2 further showed that full-length AC5 expressed in HEK293T cells could pull down only the long splice isoform, RGS9-2, or its~200-amino acid C-terminal domain but not the short isoform RGS9-1 or the core GGL/Gb 5 module, both of which lack the C-terminal region (Fig. 3F ). These observations suggest that RGS9-2, through its unique C-terminal domain, directly interacts with the catalytic domains of AC5.
m-Opioid receptor-mediated superactivation of AC5 is attenuated by the RGS9-2/Gb 5 complex
Our findings suggest that RGS9-2 action in the striatum is critical for determining the extent of sensitization of AC5. Persistent stimulation of the G i/ocoupled receptors that produce chronic activation of the G proteins leads to the homeostatic sensitization of the AC, a phenomenon known as "superactivation" (19) . A manifestation of superactivation is increased cAMP production in striatal neurons upon withdrawal from chronic opioid administration (20) (21) (22) . Most of the effects of morphine are mediated by the G i/o -coupled m-opioid receptors (m-ORs) (23, 24) . m-ORs are abundant in the striatum where they are inhibited by the RGS9-2 complex (25, 26) , and mice lacking RGS9-2 show exacerbated morphine withdrawal symptoms (26) . We therefore asked whether RGS9-2 is involved in controlling superactivation of AC5 downstream from chronic m-OR activation.
Striata of RGS9 knockout mice undergoing acute withdrawal from chronic morphine administration had higher cAMP concentrations than striata of wild-type mice (Fig. 4A) . Next, we modeled AC5 superactivation in HEK293T cells transfected with AC5 and m-OR. Removing morphine after overnight treatment induced increased cAMP concentrations, suggesting increased AC activation (Fig. 4B ). This sensitization was not observed in untransfected cells, confirming the key role of exogenously supplied AC5 in the process ( fig. S2 ). Cotransfection of RGS9-2 complex reduced this effect by nearly an order of magnitude, consistent with its role as an inhibitor of AC5 sensitization (Fig. 4B) . The GAP-deficient mutant of RGS9-2, although expressed at a similar amount as wild-type protein ( fig.  S3 ), produced only partial blockade, suggesting that the effects mediated by G protein activation play a substantial role in the development of the sensitization (Fig. 4B) . Indeed, treatment of cells with pertussis toxin (PTX), which blocks G protein activation and the resulting release of Gbg subunits, completely prevented morphine-induced superactivation (Fig. 4C) . Similarly, blocking Gbg by a scavenger peptide derived from the C-terminal G protein-coupled receptor kinase 3 (GRK3ct) prevented superactivation of AC5 (Fig. 4C ). In contrast, transfecting cells with Gbg subunits produced the opposite outcome (Fig. 4C ). Overexpressing the Ga o subunit did not prevent the development of superactivation but significantly reduced the stimulatory effect of Gbg overexpression.
To obtain a better mechanistic picture of the AC5 superactivation, we analyzed the real-time kinetics of this process in intact cells by imaging cAMP dynamics (Fig. 4D ). Termination of m-OR signaling caused a rapid increase in the concentration of cAMP, which plateaued within 2 to 3 min (Fig. 4E ). The addition of the RGS9-2 complex substantially slowed the speed of the cAMP accumulation and reduced the maximal extent of the response (Fig. 4 , E and F). Overall, these observations indicate that the RGS9-2 complex regulates the extent of superactivation of AC5, not only by directly interacting with AC5 but also by controlling the availability of the Gbg subunits through its GAP activity. 
RGS9-2 inhibits signaling through Gbg subunits by preferentially accelerating the GTPase activity of Ga o
Our results suggest that the GAP activity of RGS9-2 plays an important role in antagonizing the sensitizing action of the Gbg subunits upon chronic stimulation of m-ORs. We therefore next tested the hypothesis that the RGS9-2/Gb 5 complex inhibits Gbg signaling indirectly by speeding up the inactivation of the Ga subunits and thus facilitating their reassociation with Gbg to form inactive heterotrimers. Stimulation of the G i/o -coupled GPCRs, including m-OR, in addition to releasing Gbg, results in the activation of both Ga i and Ga o subunits that have differential effects on AC activity. We therefore examined the relative impact of the RGS9-2 complex on Gbg signaling mediated by Ga i and Ga o . We used a cell-based system in which Gbg interaction with its model effector GRK was monitored by changes in the signal from a bioluminescence resonance energy transfer (BRET) reporter (Fig. 5A) . Stimulation of m-ORs with morphine resulted in robust release of the Gbg subunits when either Ga i or Ga o was used in the assay. Virtually no signal was detected in the absence of exogenously supplied Ga subunits or m-ORs, indicating that endogenous Ga and GPCRs do not substantially contribute to the Gbg response being monitored ( fig. S4 ). The speed of the Gbg mobilization was the same for both Ga subunits (Fig. 5, B and C) . Inactivation of m-ORs by the addition of the antagonist naloxone resulted in fast termination of the Gbg-effector interaction as reported by the reduction in the BRET signal (Fig. 5, B and D) . Termination of Gbg signaling followed similar kinetics when either Ga i or Ga o was used in the assay. Introduction of the RGS9-2/Gb 5 complex resulted in substantial acceleration of the Gbg deactivation kinetics (Fig. 5 , ) subjects. The control group received saline instead of morphine and was analyzed separately. *P < 0.05 (one-way ANOVA followed by post hoc Tukey's test, n = 4 mice). (B) Effects of RGS9-2 complexes on AC superactivation induced by morphine withdrawal in transfected HEK293T cells. *P <0.05, **P < 0.01, comparison with respective no RGS groups; # P < 0.05, comparison between indicated groups (one-way ANOVA followed by post hoc Tukey's test, n = 5). (C) Effect of Gbg blockade on AC superactivation in transfected HEK293T cells. Cells were treated with PTX and morphine. *P < 0.05 for morphine effect on cAMP induction, # P < 0.05 for the effect of Gbg, and † P < 0.05 for the effect of Ga o (one-way ANOVA followed by post hoc Tukey's test, n = 3 reactions). (D) Assay design for monitoring real-time changes in cAMP concentration. (E) Time course of cAMP change upon AC5 superactivation. The m-OR antagonist naltrexone (NTX) was added to cells pretreated with morphine at the indicated time point, and the normalized change in FRET ratio, which reflects the change in cAMP concentration, was continuously recorded in live cells. (F) Quantification of the effect of the RGS9-2 complex on the maximum amplitude of the cAMP change (peak FRET ratio) and the speed of the increase in cAMP concentration (1/t). To determine t, we fitted the response curve by a single exponential function. **P < 0.01 (t test, n = 8 cells).
B and D) without affecting the abundance of the G proteins or reporter constructs in the assay ( fig. S5) . However, the RGS9-2 complex differentially affected termination of Gbg signaling by Ga i or Ga o , making responses in the Ga o -based system substantially more transient. This result is consistent with the ability of RGS9-2 to accelerate the GTPase activity of Ga o to a greater extent than that of Ga i , which has been previously demonstrated in vitro (15) , and suggests a mechanism for why RGS9-2 more strongly affects stimulatory Gbg action compared to inhibitory Ga i actions on the AC activity upon persistent activation of Ga i/o -coupled GPCRs.
Temporal resolution of AC5-mediated cAMP signaling is shaped by RGS activity RGS proteins accelerate the response kinetics in the G protein pathways that signal to ion channels (27) (28) (29) . However, the effects of RGS proteins on the kinetics of AC signaling are not known. Given the physical association between RGS9-2 and AC5, we hypothesized that, in addition to modulating AC5 sensitization, the RGS9-2 complex may also be involved in controlling the temporal characteristics of GPCR signaling to AC5. To test this possibility, we used a model of antagonistic AC regulation by Ga s and Ga i during acute GPCR signaling (Fig. 6A) . We reasoned that although Ga i is not the preferred substrate for the RGS9-2 complex compared to Ga o (15, 16) , its direct effect on AC activity presents a convenient way to study the regulatory influence of RGS proteins that are common for both Ga i and Ga o subunits.
Stimulation of cells with the agonist of the Ga s -coupled b-adrenergic receptor (b-AR) resulted in a rapid increase in cAMP concentration that plateaued in about 5 min (Fig. 6B) and persisted for at least 25 min ( fig. S6 ). However, concurrent application of morphine to stimulate the m-OR caused progressive inhibition of AC5 activity by activating Ga i overexpressed in the cells and resulted in a decrease in cAMP concentration to baseline values (Fig. 6B) . Inactivation of the m-OR with the antagonist naltrexone while continuing to stimulate b-AR reversed the inhibitory effect and restored the cAMP concentration (Fig. 6B) . Transfection of the RGS9-2 complex substantially accelerated the recovery of cAMP concentration back to the peak values after termination of the m-OR-Ga i signaling (Fig.  6C) . At the same time, the extent of the response or the onset phase of the m-ORmediated inhibition was not affected by RGS9-2 in this acute signaling paradigm (Fig. 6D) . These effects of RGS9-2 complex appear to be mediated exclusively by its GAP activity because the N364H mutant failed to alter the kinetics of the AC5 disinhibition (Fig. 6D) . These findings indicate that the RGS/Gb 5 complexes regulate the temporal characteristics of GPCR-mediated regulation of AC5 in addition to controlling its sensitization upon chronic stimulation of G protein pathways.
DISCUSSION
The key result from our study is the finding that RGS/Gb 5 complexes play a major role in controlling AC activation and sensitization. Many of the AC isoforms show dual regulation by G proteins: They are activated by Ga s but are acutely inhibited by Ga i (30) . However, persistent activation of many inhibitory G i/o -coupled GPCRs results in paradoxical increases in AC activity, a phenomenon referred to as sensitization or superactivation (19) . This plasticity mechanism has been proposed to play an important role in mediating adaptive changes in neural signaling in various processes that demonstrate a sensitization component, such as sexual behavior (31), locomotor potentiation (32) , and drug addiction (33) . The molecular changes leading to AC sensitization are not well understood. However, most studies agree that the sensitization involves liberation of the bg subunits of G i/o proteins, which enhance modulation of AC by Ga s either directly by bg binding or indirectly through the action of stimulatory protein kinases such as Raf-1 (19) . Notably, the activity of the striatal AC isoforms AC5/6 is potentiated by both phosphorylation by Raf-1 (34, 35) and binding to bg (17) .
Our study shows that the elimination of RGS/Gb 5 proteins markedly enhances the activity of AC in the striatum. Although we cannot rule out the impact of possible adaptations on cAMP homeostasis in a mouse model that lacks all R7 RGS proteins, our dissection of potential mechanisms suggests that the key role is played by the RGS9-2/Gb 5 complex, which uses a dual mechanism to control AC5 activity. First, direct physical association of RGS9-2/Gb 5 with AC5 inhibits its basal activity and reduces the sensitivity to the activation by the Ga s . Second, during persistent activation of the Ga i/ocoupled receptors, the GAP activity of the RGS9-2/Gb 5 additionally promotes heterotrimer reformation and thus reduces the pool of free bg subunits that promote AC5 sensitization. In addition to RGS9-2, other R7 RGS isoforms are likely contributing to setting AC5 activity because the surge in basal cAMP concentration seen in Gb 5 knockout is not present in striata of mice lacking only RGS9-2. Our model proposes that R7 RGS protein complexes are effective inhibitors of AC activity, making it possible to achieve changes in cAMP concentration by modulating the abundance or activity of the R7 RGS proteins. Indeed, drugs of abuse alter the abundance of RGS9-2 in the striatum (36), suggesting that this mechanism likely contributes to the development of dependence by regulating the extent of AC superactivation.
Enhanced dissociation of the heterotrimers upon elimination of RGS/Gb 5 should, in addition to increasing the pool of free Gbg, also result in the increased availability of activated Ga i -GTP, which inhibits AC activity. This could theoretically negate the stimulatory effect of the Gbg or possibly lead to inhibition of ACs. The latter is seen upon acute stimulation of G i/o -coupled GPCRs. We think that the reason why the sensitization of AC by Gbg prevails over its inhibition by Ga i upon loss of RGS is that R7 RGS proteins more potently regulate the activity of the Ga o isoform, which does not exert regulatory effects on AC5 (37, 38) . Indeed, we show that the RGS9-2/Gb 5 complex exerts a much stronger regulatory effect on Gbg signaling with Ga o rather than Ga i subunits in the m-OR signaling pathway reconstituted in living cells. This observation is consistent with a reported preference of RGS/Gb 5 complexes for Ga o over Ga i during stimulation of GTP hydrolysis (15, 16) . This model is also supported by findings in transfected C6 cells in which endogenous RGS proteins suppress superactivation of ACs by specifically regulating Ga o proteins (39) . Our findings suggest that inhibition of AC activity by RGS proteins may be a general phenomenon. Previous studies identified RGS2 as a binding partner of several AC isoforms including AC5 (40) . The N terminus of RGS2 binds to the catalytic C1/C2 domains of AC5 and inhibits its activity (41) . Analysis of the sequence features of the N terminus of RGS2 and the C terminus of RGS9-2 reveals that both of these regions are predicted to be intrinsically disordered. Intrinsic disorder elements in proteins are thought to underlie their functional flexibility and are hot spots for protein-protein interactions (42, 43) . This observation suggests that binding to intrinsically disordered proteins, including RGS proteins, may be a common feature that AC isozymes use for fine-tuning their activity, as (C) Quantification of the effects of the RGS9-2 complexes on kinetics of the cAMP change during Ga i deactivation (OFF phase). Time from the baseline to the peak after naltrexone application, and the speed of the cAMP induction (1/t) were quantified. To determine t, we fitted the response curve by a single exponential function. RGS9-2 significantly decreased the time to reach peak cAMP concentrations after Ga i inactivation. *P < 0.01 (one-way ANOVA followed by post hoc Tukey's test comparison with no RGS control groups, n = 6 to 9 cells). (D) Quantification of the effects of the RGS9-2 complexes on the kinetics of the change in cAMP concentration. The time from baseline to maximal peak response after isoproterenol application and from peak to basal after morphine application were defined as Ga s ON and Ga i ON phases, respectively.
well as for modulating the regulation by subunits of the heterotrimeric G proteins. The RGS/Gb 5 complexes, as well as other RGS proteins that specifically regulate GTPase activity of G i/o proteins, are not traditionally thought to affect signaling through G s -coupled GPCRs. However, our findings introduce a mechanism by which RGS proteins can act as inhibitors of signaling through G s -coupled GPCRs as well. By reducing the availability of the stimulatory Gbg subunits and limiting the sensitivity of the AC regulation by Ga s , RGS proteins act to reduce the extent of cAMP formation induced by the activation of G s -coupled GPCRs. From the perspective of the striatal GPCR signaling, this mechanism suggests that the RGS9-2/Gb 5 complex, in addition to regulating G i/o -coupled m-OR and D 2 dopamine receptors, is also likely to be involved in controlling signaling through the G s -coupled D 1 receptor.
Finally, we would like to stress the functional importance of scaffolding of AC with RGS proteins, which we found played a prominent role in increasing the temporal resolution of cAMP signaling. It was previously demonstrated that RGS protein action is required to reconstitute rapid gating of the ion channel by the G proteins (44) . Here, we extend these observations and demonstrate that the temporal characteristics of the cAMP signaling pathway are also controlled by RGS proteins. Although the regulation of cAMP signaling occurs on a slower time scale relative to the ion channels, RGS activity nevertheless substantially accelerates the ability of ACs to recover from the regulatory influence imposed by G proteins, thus enabling greater frequency of cAMP fluctuations.
MATERIALS AND METHODS

Mice and DNA constructs
The Gb5 −/− (45) and RGS9 −/− (46) mice were generated previously and were backcrossed with C57/Bl6 mice for six generations. Littermates for Gb5 −/− (2 to 4 months old) derived from heterozygous breeding pairs were used for all experiments. All procedures were approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute.
Cloning of full-length Gb 5 , R7BP, RGS9-2, full-length AC5, and fragments was described previously (17, (47) (48) (49) (50) . The N364H mutation in mouse RGS9-2 was introduced by the QuikChange site-directed mutagenesis kit (Stratagene). BRET reporter constructs Venus 155-239 -Gb 1 , Venus 1-155 -Gg 2 , and masGRKct-Rluc8 were gifts from N. A. Lambert (Medical College of Georgia), and hemagglutinin-tagged m-OR (HA-MOR) was a gift from P.-Y. Law (University of Minnesota). The cAMP fluorescence resonance energy transfer (FRET) sensor mTurquoise-Epaccp173 Venus-Venus was provided by K. Jalink (The Netherlands Cancer Institute). Rat complementary DNA (cDNA) mammalian expression clones for Ga i1 , Ga i2 , and Ga o in pCMV5 were gifts from H. Itoh (Nara Institute of Science and Technology).
Recombinant proteins and membrane preparations
Recombinant complexes of Gb 5 with His-tagged full-length RGS9-2, RGS9-2 (N364H), RGS9-1, RGS6, RGS7, or GGL fragment of RGS9 (amino acids 193 to 284) were expressed in the Sf 9/baculovirus system and purified as described (51, 52) . Similarly, expression and purification of the His-tagged C-terminal fragment of the RGS9-2 (amino acids 467 to 675), Gb 1 g 2 , and C1 and C2 domains of canine AC5 were also described (53, 54) . Glutathione S-transferase (GST)-tagged N-terminal domains of AC5 were expressed in BL21 (DE3) Escherichia coli strain and purified by affinity chromatography on glutathione-Sepharose 4B beads (GE Healthcare). The purity of the recombinant proteins was assessed by Coomassie staining after gel separation and was found to be at least 70%.
For membrane preparation, striatal tissues or Sf 9 cell membranes were homogenized in buffer containing 250 mM sucrose, 20 mM Hepes (pH 8.0), 1 mM EDTA, 2 mM MgCl 2 , 1 mM dithiothreitol (DTT), and protease inhibitors. The homogenate was centrifuged at 2000g to remove nuclei, followed by centrifugation at 25,000 rpm in Beckman SW28.1 rotor for 35 min in 23/43% sucrose gradient to isolate membrane fraction. The plasma membranes were carefully collected from the layer at the 23/43% interface.
Determination of cAMP concentration and assays for AC and PKA activity Brain tissue or HEK293T cells were homogenized in 0.1 N HCl. For striatum tissues, 20 ml of HCl was added per milligram of tissue, and samples were homogenized by passing through a series of needles with decreasing gauges. Twenty-four hours after transfection, cells were stimulated with forskolin (5 and 1 mM for without AC5 and with AC5 transfection, respectively) or 100 nM isoproterenol for 5 min. For cAMP superactivation assays, cells transfected with m-OR and AC5 with or without indicated components were pretreated with 1 mM morphine overnight. Blocking Gbg signaling was achieved with a construct encoding the C-terminal sequence of Gbg effector molecule GRK3 (GRK3ct) (55) , which was transfected into cells together with HA-MOR and Flag-AC5 at a 2:3:1 ratio. G protein signaling was blocked by PTX (100 ng/ml) treatment for 16 to 18 hours. m-OR signaling was terminated by abruptly changing the medium followed by 5 min of incubation in fresh medium. Cells were then lysed in 400 ml of HCl per well in a 48-well plate (2 × 10 5 cells) for 30 min. Lysates were centrifuged at 600g for 10 min. Supernatants were collected and diluted 50-fold, and cAMP concentrations were quantitated with a cAMP enzyme immunoassay kit following acetylated version protocol (Assay Designs) according to the manufacturer's instructions. The activity of full-length AC in membrane preparations (1 mg of total protein per reaction) was determined in membrane preparations as described previously (56) . Striatal membranes (1 mg of protein) prepared from Gb 5 knockouts (Gb 5
−/−
) and their wild-type littermates (Gb 5 +/+ ) were transiently stimulated with DHX (10 mM). For basal AC activity assays, striatal membranes or Sf 9 membranes expressing AC5 (1 mg) were treated with purified RGS protein complexes at indicated concentrations for 20 min on ice. For dose-response curves of Ga s -GTPgS-stimulated AC activity experiments, striatal membranes were preincubated with 0.5 mM RGS9-2/Gb 5 wild-type or N364H mutant protein or with 0.2 mM Gb 1 g 2 for 20 min on ice and then subjected to AC activity assay transiently stimulated with increasing doses of Ga sGTPgS as indicated. The resulting cAMP in the sample was determined by cAMP Direct EIA Kit. PKA activity was determined by the MESACUP protein kinase assay kit (MBL Ltd.).
Preparation of protein extracts and Western blotting
Striatal tissue (~15 mg) or transfected HEK293T cells were homogenized by sonication in~300 ml of detergent buffer [1× phosphate-buffered saline (PBS), 150 mM NaCl, 1% Triton X-100 containing complete protease inhibitor cocktail (Roche), and phosphatase inhibitor cocktails 1 and 2 (Sigma)]. The homogenate was centrifuged at 15,000g for 15 min at 4°C. The resulting supernatant was resolved on SDS-polyacrylamide gel electrophoresis gel, transferred onto polyvinylidene difluoride membrane, and subjected to Western blot analyses by probing with pan-specific antibodies [AC5/6 (Santa Cruz Biotechnology), DARPP-32 (Chemicon), Flag (M2, Sigma), RGS9-2 (CT) (57) , and anti-Gb 5 (ATDG) (58)] or phospho-specific antibodies [p-DARPP-32 (T34, Cell Signaling Technology) and p-PKA substrate (Cell Signaling Technology)].
Immunoprecipitation
The interaction between RGS9-2 and AC in native tissues was studied by probing AC activity after immunoprecipitation of RGS9-2 from striatal extracts. Fresh dissected striatal tissue (~50 mg) was homogenized by passing through a series of needles with decreasing gauges in 600 ml of homogenization buffer [50 mM Hepes (pH 7.4), 5 mM EDTA, 100 mM NaCl, 1 mM DTT, 10% glycerol] containing proteinase inhibitor cocktail. The nonionic detergent C 12 E 9 (0.6%) was added to the buffer, and the lysate was homogenized and centrifuged at 16,000g for 15 min. The supernatant was incubated with 5 mg of RGS9-2 antibodies and 10 ml of protein G beads for 2 hours at 4°C. Beads were washed three times with 500 ml of wash buffer [50 mM Hepes (pH 7.4), 1 mM EDTA, 1 mM MgCl 2 , 150 mM NaCl, 0.05% C 12 E 9 ]. After the final wash, beads were resuspended in 240 ml of the assay buffer [50 mM Hepes (pH 7.4), 1 mM EDTA, 1 mM MgCl2, 0.04% C 12 E 9 ] containing 100 mM forskolin and proteinase inhibitors, incubated for 10 min at 30°C, and processed for determination of cAMP concentration. In reciprocal immunoprecipitation assays, Flag-tagged full-length AC5 expressed in HEK293T cells was immobilized on protein G beads (GE Healthcare) coated with anti-Flag antibody. The beads were mixed with striatal tissue lysate, and the mixture was incubated at 4°C for 1 hour. RGS9-2 and Flag-tagged AC5 were co-immunoprecipitated upon their co-expression in HEK293T cells following similar procedures.
Measurement of real-time cAMP dynamics by ratiometric FRET imaging
Real-time changes in cAMP concentration were studied in live HEK293T cells with FRET-based mTurquoise-Epaccp173 Venus-Venus reporter (59) . Twenty-four to 48 hours after transfection, cells grown on coverslips were washed with Hepes-Hanks' buffer (137 mM NaCl, 5.4 mM KCl, 0.4 mM KH 2 PO 4 , 0.3 mM Na 2 HPO 4 , 3 mM NaHCO 3 , 0.5 mM MgCl 2 , 0.4 mM MgSO 4 , 1.3 mM CaCl 2 , 20 mM Hepes, 5.6 mM glucose, pH 7.4), mounted in a POCmini perfusion chamber (PeCon GmbH), and imaged by a Leica CTR6000 inverted microscope with electron-multiplying charge-coupled device camera (Hamamatsu Corporation) with MetaFluor software (version 7.6.1.0, MDS Analytical Technologies). The chamber was constantly perfused with Hepes-Hanks' buffer by gravity flow (~2 ml/min). Several healthy-looking cells were identified in a field of view with ×20 objective and defined as regions of interest by outlining their soma. Subsequent analysis was performed for only these regions. Cells were excited by 30-ms flashes of light with 430/24-nm excitation filter. Emitted light was split by a DV2 dual-view image splitter (MAG Biosystems) into two simultaneously recorded channels with band-pass filters of 470/24 and 535/30 nm, respectively. The interflash interval for image acquisition was set to 5 s. For each recording, the inverse FRET ratios were calculated by dividing the fluorescence intensity in the 470-nm channel by that recorded in the 535-nm channel. The resulting value (R) was normalized against the average baseline value from 10 to 20 frames recorded before stimulation (R 0 ). Alternatively, the R 0 value was subtracted as a background, and the resulting difference was normalized against the maximal value recorded upon cellular response (R max ). For measuring the acute inhibitory effects of Ga i , cells were transfected with mTurquoise-Epac- For the sensitization studies, transfected cells were pretreated with morphine (1 mM) or vehicle for 16 to 18 hours. Cells were then washed and equilibrated in Hepes-Hanks' buffer containing morphine (1 mM) or vehicle followed by the perfusion of 50 nM naltrexone in Hepes-Hanks'. Cells were first stimulated with 50 nM b-AR agonist isoproterenol for 2 min. Morphine (10 mM) was then applied to cells for 20 min followed by 5 min of perfusion of 10 mM naltrexone while keeping isoproterenol in the medium.
Pull-down assays
Pull-down assays were performed in two ways. In the first method, the reaction consisted only of purified recombinant proteins. These assays were performed as described previously (60) . Briefly, 100 pmol of purified GSTtagged N terminus of human AC5 and 100 pmol of purified RGS9-2/Gb 5 were co-incubated with 20 ml of glutathione agarose beads (GE Healthcare). Alternatively, RGS9-2/Gb 5 proteins were incubated with purified recombinant C1 and C2 proteins (100 pmol each), specific RGS9-2 antibody, and 10 ml of protein G beads (GE healthcare). In both cases, incubations were performed in 500 ml of the binding buffer [20 mM tris (pH 7.2), 300 mM NaCl, 0.25% n-dodecanoylsucrose, bovine serum albumin (50 mg/ml)] for 30 min at 4°C. The beads were washed three times by binding buffer, and retained proteins were eluted by the SDS sample buffer.
In the second method, we immobilized Flag-tagged full-length AC5 and studied its ability to retain recombinant RGS9-2 mutants. HEK293T cells transfected with Flag-tagged full-length AC5 were lysed in the lysis buffer (1× PBS buffer + 150 mM NaCl + 0.5% n-dodecanoylsucrose). The homogenate was centrifuged at 15,000g for 15 min at 4°C. Supernatant was incubated with anti-Flag antibody and protein G beads (GE Healthcare) for 1 hour at 4°C. After two washes with the lysis buffer, the beads were washed once and incubated with purified RGS proteins (100 pmol) previously precleared with anti-Flag antibodies and protein G beads and incubated at 4°C for 1 hour. As before, proteins were eluted from the beads with SDS sample buffer.
Morphine treatment and withdrawal
Morphine withdrawal paradigm was implemented as previously described (26) . Briefly, mice were injected intraperitoneally with escalating doses of morphine (20, 40, 60, 80 , 100, and 100 mg/kg) every 8 hours. Control mice were injected with saline following the same schedule. Two hours after the last morphine/saline injection, naloxone (1 mg/kg) was administered by subcutaneous injection. All mice that received morphine showed prominent signs of withdrawal (including wet dog shakes, back walking, and paw shaking) 30 min after naloxone injection. At that point, mice were euthanized; their striata were dissected and processed for the analysis of cAMP content as described above.
Monitoring real-time kinetics of Gbg signaling by fast kinetic BRET assay Agonist-dependent cellular measurements of BRET between masGRKctRluc8 and Gb 1 g 2 -Venus were performed to visualize the action of G protein signaling in living cells as previously described with slight modifications (61) . HEK293T/17 was transfected with Lipofectamine LTX (8 ml per dish) and PLUS (5 ml per dish) reagents. m-OR, Ga (Ga o , Ga i1 ), Venus 155-239 -Gb 1 , Venus 1-155 -Gg 2 , masGRKct-Rluc8, RGS9-2, Gb 5 , and R7BP constructs were used at a 1:2:1:1:1:1:1:1 ratio. BRET measurements were made with a microplate reader (POLARstar Omega; BMG Labtech) equipped with two emission photomultiplier tubes, allowing us to detect two emissions simultaneously with resolution of 50 ms for every data point. All measurements were performed at room temperature. The BRET signal is determined by calculating the ration of the light emitted by the Gb 1 g 2 -Venus (535 nm) over the light emitted by the masGRKct-Rluc8 (475 nm). The average baseline value recorded before agonist stimulation was subtracted from BRET signal values, and the resulting difference (R) was normalized against the maximal value (R max ) recorded upon agonist stimulation.
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www.sciencesignaling.org/cgi/content/full/5/239/ra63/DC1 Fig. S1 . The N364H mutation abolishes GTPase activity of RGS9-2 and its effects on G protein subunit reassociation. 
